Drug intelligence / Profile preview

japanese encephalitis virus vaccine + Advax

Development stage
Preclinical
Lead developer
Vaxine
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Japanese encephalitis virus vaccine + Advax is a recombinant protein vaccine candidate developed by Vaxine. It consists of recombinant flavivirus antigens formulated with Vaxine's proprietary Advax adjuvant, which is based on delta-inulin. The vaccine is designed to provide broad-spectrum protection against Japanese encephalitis virus (JEV) and related flaviviruses that cause encephalitis. Preclinical data suggests that the formulation induces robust immune responses and offers cross-protection against Murray Valley encephalitis virus (MVEV), Kunjin virus, and West Nile Virus (WNV). The use of the Advax adjuvant is intended to enhance the vaccine's immunogenicity while maintaining a high safety profile.

Other names
JEV + AdvaxJEV/MVEV/Kunjin/West Nile cross-protective vaccine
02

Targets

Murray Valley encephalitis virus envelope proteinJEV prM/E (Japanese encephalitis virus prM/E antigen)Kunjin virus envelope proteinE (Tick-borne encephalitis virus envelope protein)

Beyond the preview

Go deeper on japanese encephalitis virus vaccine + Advax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on japanese encephalitis virus vaccine + Advax.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call